Ann: Dimerix presentation at Bioshares Biotech Summit, page-51

@vintage ah you've fallen into the trap of assuming large population = trial success. If it was as simple as that we'd all run this trial in India and China and be done in 6 months. China is also a geographically huge country, surely the real question is how many hospitals will be opened to take advantage of the large population and how effective those hospitals have been at recruiting into FSGS trials before, can they be relied on to do things properly. Travere did not run DUPLEX FSGS trial in China. Why? Were they stupid or did they know something DXB doesn't? This trial is in the 3rd most populous country on earth, US, but that doesn't seem to have made it move quickly. But I'll take your advice and look out for the quarterlies if you are saying they will shed some more light on DXB's strategy to dealing with its trial performance issues.

@Bathurst I think you'll find it's +245 days (i.e. + 35 weeks), not +200.